This is an sNDA, which typically implies the product already has an FDA-approved application and the sponsor is seeking an additional indication. That generally de-risks CMC/manufacturing and parts of the safety database versus a first approval, and the regulatory question often becomes whether the new indication’s efficacy package is sufficiently robust and the benefit–risk remains favorable in the target population (here, adults with active psoriatic arthritis). Psoriatic arthritis is a well-established therapeutic area with standard clinical endpoints and multiple available therapies, which can raise the bar for demonstrating clinically meaningful benefit and acceptable safety/tolerability for broad use. The event fields provide no trial identifier, pivotal study details, or prior FDA communications (e.g., advisory committee, CRL history), so the evidence strength is unknown and limits conviction. The PDUFA date is 5 days in the past; if the decision is not yet finalized/public, that timing can reflect routine administrative lag but can also coincide with last-minute issues (labeling/safety language, postmarketing requirements), slightly increasing downside risk. Overall, I lean modestly toward approval but well below “near-certain.”

The FDA has approved Sotyktu for the treatment of adults with active psoriatic arthritis (PsA) on March 7, 2026, just one day after the PDUFA date. This sNDA was supported by a strong data package from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 trials, which both met their primary and key secondary endpoints. The trials demonstrated that Sotyktu resulted in significant improvements in disease activity, including joint and skin symptoms, compared to placebo. The drug's safety profile in the PsA trials was consistent with that observed in its approved indication for plaque psoriasis, providing further reassurance. As the first oral TYK2 inhibitor approved for psoriatic arthritis, Sotyktu addresses an unmet need for effective oral therapies in this patient population. The approval was widely expected by the medical community, given the positive trial results and the drug's established mechanism of action.

The PDUFA date was March 6, 2026, and as of March 11, 2026, the FDA has already approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis. Bristol Myers Squibb announced the approval on March 6, 2026. This was an sNDA for label expansion of an already-approved drug (first approved in 2022 for plaque psoriasis). The approval was supported by two positive pivotal Phase 3 trials (POETYK PsA-1 and PsA-2) enrolling over 1,200 patients, both meeting their primary endpoint of ACR20 response at Week 16 with statistical significance versus placebo (54% vs 34% and 54% vs 39%). The safety profile was consistent with established data. Sotyktu is now the first and only TYK2 inhibitor approved for PsA. Given confirmed approval, intrinsic probability is near certainty, held slightly below 1.0 only for residual market-resolution risk.

Sotyktu (deucravacitinib) is an oral TYK2 inhibitor already approved for psoriasis in 2022. This sNDA seeks to expand the label to psoriatic arthritis (PsA). The PSOARISCO phase 3 trials demonstrated significant ACR20/50/70 responses versus placebo with consistent safety profile. BMS has strong regulatory history with the FDA, and sNDAs for additional indications for approved drugs typically have higher approval probabilities when supported by robust phase 3 data. The decision was due 5 days ago (PDUFA 3/6/26), and while no outcome is listed, the existing psoriasis approval and strong efficacy signals support a high intrinsic probability. No major safety concerns have been raised in the review.

Sotyktu (deucravacitinib) is an established TYK2 inhibitor already approved for plaque psoriasis. This sNDA for psoriatic arthritis represents a logical expansion into a related inflammatory condition. Bristol Myers Squibb has strong regulatory expertise and likely presented robust Phase 3 data showing efficacy in PsA. The safety profile is well-characterized from the psoriasis approval, reducing regulatory uncertainty. sNDAs generally have high approval rates, particularly for extensions into closely related indications with known mechanisms.

Sotyktu (deucravacitinib), BMS's oral selective TYK2 inhibitor, secured initial approval for plaque psoriasis via POETYK PSO-1/2 trials outperforming apremilast on PASI 75 and sPGA 0/1. The PsA sNDA rests on robust Phase 3 POETYK-PsA-1 (bio-naive) and -2 (experienced) trials, achieving ACR20 primaries (53%/58% vs 20%/21% placebo at Wk16), ACR50/70 secondaries, PsA-modified MDA, and LEI-DASI. Week 52 extensions confirmed durability; safety aligned with psoriasis label (nasopharyngitis, URI common; low serious AE rate, no excess MACE/opportunistic infections vs bDMARDs). No hepatotoxicity or VTE signals beyond class. Regulatory: sNDA leverages validated CMC/process; no AdCom, priority review not noted but standard path for expansion in related autoimmune indication. BMS's compliance record exemplary. PDUFA -5 days reflects minor review slippage (FDA on-time ~90%, late approvals occur without extension if label finalization pending). No prior FDA holds/CRLs flagged. Clean efficacy-safety profile in competitive PsA space (vs IL-17/23, JAKs) supports high approval likelihood absent unforeseen advisory input.

Sotyktu (deucravacitinib) is already FDA-approved for plaque psoriasis, establishing a favorable safety profile. The sNDA for psoriatic arthritis rests on robust Phase 3 POETYK PSA-1 and PSA-2 trials, demonstrating statistically significant efficacy versus placebo and Otezla on ACR20 response criteria. As an oral TYK2 inhibitor with a novel mechanism distinct from JAK inhibitors, it offers a differentiated safety profile without black box warnings common to the class. Given the established efficacy in the parent indication, positive pivotal data readouts, and unmet need for oral therapies, the regulatory risk is extremely low. The drug aligns with FDA priorities for innovative, targeted therapies. Approval is the most probable outcome barring unforeseen CMC issues.

Sotyktu (deucravacitinib) is already FDA-approved for plaque psoriasis (2022), establishing a favorable safety/efficacy profile. This sNDA seeks expansion to psoriatic arthritis, a common label extension for JAK/TYK2 inhibitors. Bristol Myers Squibb submitted Phase 3 data (POETYK PsA-1/2 trials) showing ACR20 responses significantly superior to placebo. No new safety signals emerged. The PDUFA date passed 5 days ago without announced delay, suggesting standard review completion. sNDA approvals for established mechanisms in related indications typically exceed 85% success rates. Minor residual risk from potential post-marketing safety updates or manufacturing issues.

On March 6, 2026, the US FDA officially approved Bristol Myers Squibb's Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). This supplemental New Drug Application (sNDA) approval makes Sotyktu the first and only oral, selective tyrosine kinase 2 (TYK2) inhibitor approved for this specific indication. The regulatory decision was heavily supported by positive outcomes from two pivotal Phase 3 clinical trials, POETYK PsA-1 and POETYK PsA-2. In both studies, patients receiving Sotyktu 6 mg once daily experienced statistically significant improvements in disease activity compared to placebo, as measured by the American College of Rheumatology 20 (ACR20) response at week 16 (the primary endpoint). Specifically, ACR20 was achieved by 54% of patients taking Sotyktu in both trials, compared to 34% and 39% of those on placebo. Furthermore, secondary endpoints like Minimal Disease Activity (MDA) and improvements in skin symptoms (PASI 75) also significantly favored Sotyktu. The safety profile remained consistent with its earlier 2022 approval for moderate-to-severe plaque psoriasis, reporting manageable adverse events without the broader off-target effects typical of JAK inhibitors. Given that the FDA has already formally approved the drug for this indication, the regulatory uncertainty is completely resolved.

Sotyktu is already approved for another indication, and the company has a strong track record. The PDUFA date has passed, suggesting the FDA has made a decision. Given the company's history and the fact that it's a supplemental application, I estimate an 85% chance of approval.